Genmab AS ADR earnings beat by $0.20, revenue fell short of estimates

Genmab reported positive phase III trial results for Epkinly, Rina-S, and petosemtamab, with Epkinly showing a hazard ratio of 0.49 in the EPCORE DLBCL-2 trial. Sales for Epkinly and Tivdak grew 47% and 9% year-over-year, respectively, to $491M and $131M in the first nine months of 2026. The company is preparing for potential launches in early lines of DLBCL and other indications.

Moody's revised Genmab's outlook to positive from stable, affirming its Ba2 rating. The agency expects revenue growth and debt reduction to improve credit metrics. Adjusted EBITDA is projected to rise to $1.5B-$1.7B by 2025. Liquidity remains strong with $1.9B in cash. However, reliance on Darzalex royalties and upcoming patent expirations pose risks.

Genmab (GMAB) shares fell 4.9% after Q3 revenue of $1.19B missed estimates, though EPS beat. Epkinly sales grew 47% but lagged Jyske Bank's forecast. Full-year guidance remained unchanged, disappointing some analysts. Higher costs reduced net profit. The company maintained its revenue and earnings outlook but did not raise it, despite recent clinical trial successes.

Genmab reported a 22% revenue increase in Q3 2026, driven by strong performance of Epkinly and other pipeline assets. The company expects peak sales of over $3B for Epkinly, $2B for Rina-S, and multibillion for pitucentamab. Management expressed confidence in growth despite the Darzalex royalty expiration, citing diversified growth and strong Phase 3 data. Epkinly showed a 47% increase, and the rest of the portfolio grew by 30%.

Genmab reported Q3 earnings, highlighting 9% sales growth for TIVDAK to $131M. EPKINLY met its primary endpoint in DLBCL, with a hazard ratio of 0.49. Rina-S and petosemtamab also showed positive trial results. Genmab reaffirmed peak sales estimates and plans for potential filings. The company aims to grow operating profit in 2027 and reduce leverage.

Genmab reported 9M revenue growth of 22% and adjusted operating profit up 9%. The company announced three positive phase III trial results, maintaining FY26 guidance and targeting profit growth and gross leverage below 3x by 2027, according to its Q3 2026 earnings transcript.